Shikiar Asset Management Inc. held its position in Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,300 shares of the biopharmaceutical company’s stock at the end of the second quarter. Shikiar Asset Management Inc.’s holdings in Pfizer were worth $363,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Catamount Wealth Management increased its stake in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares in the last quarter. Stuart Chaussee & Associates Inc. increased its stake in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares in the last quarter. Oakmont Partners LLC acquired a new stake in shares of Pfizer during the second quarter valued at about $211,000. Financial Strategy Network LLC acquired a new stake in shares of Pfizer during the first quarter valued at about $205,000. Finally, Moon Capital Management LLC acquired a new stake in shares of Pfizer during the second quarter valued at about $237,000. 69.66% of the stock is owned by institutional investors and hedge funds.
Pfizer Inc. (NYSE:PFE) traded down 0.31% during trading on Friday, hitting $32.66. The company had a trading volume of 15,569,339 shares. The company’s 50 day moving average price is $34.02 and its 200-day moving average price is $34.27. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39. The stock has a market capitalization of $198.10 billion, a price-to-earnings ratio of 28.95 and a beta of 0.86.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. During the same quarter last year, the firm posted $0.56 EPS. The company’s revenue was up 10.9% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post $2.46 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be issued a $0.30 dividend. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 annualized dividend and a dividend yield of 3.67%. Pfizer’s payout ratio is currently 95.24%.
Several brokerages have issued reports on PFE. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.08 price target for the company in a report on Tuesday, August 2nd. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Pfizer in a report on Monday, September 26th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $54.00 price target on shares of Pfizer in a report on Monday, June 27th. BMO Capital Markets reaffirmed a “buy” rating and set a $40.00 price target on shares of Pfizer in a report on Thursday, July 21st. Finally, JPMorgan Chase & Co. set a $40.00 price target on Pfizer and gave the company a “buy” rating in a report on Monday, July 25th. Eleven analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $38.59.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.